your catalyst to a lucrative business n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Biosimilars Market Research Report - Global Industry Analysis PowerPoint Presentation
Download Presentation
Biosimilars Market Research Report - Global Industry Analysis

Loading in 2 Seconds...

play fullscreen
1 / 6

Biosimilars Market Research Report - Global Industry Analysis - PowerPoint PPT Presentation


  • 1 Views
  • Uploaded on

Biosimilars Industry is Expected to Grow on Account of Increasing Prevalence of Chronic Diseases

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Biosimilars Market Research Report - Global Industry Analysis' - Marsh


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
your catalyst to a lucrative business

Your Catalyst To a Lucrative Business

Biosimilars Market Research Report - Global Industry Analysis,

Size, Growth and Forecast to 2024 – Hexa Research

“Global Biosimilars market size was valued at 3.39 billion

in 2016 and is expected to grow on account of increasing

prevalence of chronic diseases such as cancer and

autoimmune disorders..”

The Global Biosimilars Market is expected to reach USD 13.1 billion by 2024 on account of increase in the prevalence of

chronic diseases such as cancer, diabetics, cardiac disorders and autoimmune diseases. Rising demand for the cost-

effective therapies is expected to drive the market in the forecast period. Biosimilars are about 30% cheaper than their

counterpart biologics. Furthermore, the patent expiry of the blockbuster drugs is anticipated to provide a lucrative

opportunity for the growth of biosimilars. For instance, a patent for Bevacizumab, sold under the trade name Avastin is

expiring in 2019.

Moreover, increasing government initiatives, speedy drug approvals and reimbursement policies are expected to boost

the market for the biosimilars in the study period. Also, market giants are adopting merger & acquisition strategies to

increase their product portfolio. For instance, in 2015, Pfizer, Inc. acquired Hospira, a key player in biosimilars market.

Browse Details of Report @ https://www.hexaresearch.com/research-report/biosimilars-market

In 2016, oncology was the largest segment, accounting for 32% market share. Increasing prevalence of cancer across the

globe is the key factor driving the growth of the market over the forecast period. For instance, according to the

American Cancer Society, an estimated 1.6 lakh people suffered from cancer in 2016. Also, increasing government

initiatives to provide cost effective treatment to cure deadly diseases will boost the penetration of biosimilar in

developing countries which in turn will increase the market for biosimilar over the forecast period. For instance, WHO

launched a pilot program for prequalifying biosimilar drug, making some of the most expensive treatments for cancer

Follow Us:

your catalyst to a lucrative business 1

Your Catalyst To a Lucrative Business

more widely available in developing countries. Under this initiative, WHO has focused on two essential drug rituximab

(principally used for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia), and trastuzumab

(for the treatment of breast cancer).

In terms of region, Europe dominates the market for biosimilars followed by North America. The dominance of Europe is

due speedy approval of the drug by European regulatory bodies. Furthermore, improving healthcare infrastructure and

ageing population is expected to drive the market over the forecast period. However, Asia Pacific is projected to be the

fastest growing region owing to the increasing disposable income of middle-class families, growing medical tourism and

improving healthcare infrastructure. Furthermore, increasing investment in R&D activities by pharmaceutical giants is

expected to boost the market in the projected period.

Hexa Research has segmented the global biosimilars market based on indication and region:

Segmentation by indication, 2014 - 2024 (USD Million)

• Blood Disorders

• Oncology

• Chronic & Autoimmune Diseases

• Others

Segmentation by region, 2014 - 2024 (USD Million)

• North America

• U.S.

• Europe

• Germany

• Asia Pacific

• China

• India

• Japan

• Rest of the world

Key players analyzed:

• Dr. Reddy’s Laboratories Ltd

• Mylan

• Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

• Pfizer Inc.

• Sandoz International GmbH

• Teva Pharmaceuticals Industries Ltd.

• Amgen Inc.

• STADA Arzneimittel AG

• Biocon

• F. Hoffmann-La Roche Ltd.

Browse Related Category Market Reports@

Follow Us:

your catalyst to a lucrative business 2

Your Catalyst To a Lucrative Business

U.S. Medical Cannabis Market: - U.S. Medical Cannabis has Numerous Health Benefits Particularly by

Patients Suffering from Cancer, Chronic Pain and Diabetes

Teeth Whitening Products Market: - Recommendations from dentist and approvals from the dental

associations encourages consumers to utilize lightening products and is anticipated to boost the market over

the coming few years

Table of Content of Biosimilars Market

Chapter 1. Market Summary

1.1. Market trends & movement

Chapter 2. Global Biosimilars Market Trends: Drivers & Opportunities

2.1. Introduction

2.2. Key industry trends

2.3. Market drivers

2.4. Market restraints

2.5. Value chain analysis

2.6. Porter's Five Forces analysis

2.7. SWOT

Chapter 3. Global Biosimilars Market Trends, By Indication

3.1. Global Biosimilars market movement, by indication, 2016 & 2024

3.1.1. Blood disorders

3.1.1.1. Market estimates and forecast, 2014 - 2024 (USD Million)

3.1.2. Oncology

3.1.2.1. Market estimates and forecast, 2014 - 2024 (USD Million)

3.1.3. Chronic & Autoimmune Diseases

3.1.3.1. Market estimates and forecast, 2014 - 2024 (USD Million)

3.1.4. Others

3.1.4.1. Market estimates and forecast, 2014 - 2024 (USD Million)

Chapter 4. Global Automotive Suspension Market Trends, By Region

4.1. Global automotive suspension market movement, by region, 2016 & 2024

4.1.1. North America

4.1.1.1. Market estimates and forecast, 2014 - 2024 (USD Million)

4.1.1.2. Market estimates and forecast, by indication, 2014 - 2024 (USD Million)

4.1.2. Europe

4.1.2.1. Market estimates and forecast, 2014 - 2024 (USD Million)

Follow Us:

your catalyst to a lucrative business 3

Your Catalyst To a Lucrative Business

4.1.2.2. Market estimates and forecast, by indication, 2014 - 2024 (USD Million)

4.1.3. Asia Pacific

4.1.3.1. Market estimates and forecast, 2014 - 2024 (USD Million)

4.1.3.2. Market estimates and forecast, by indication, 2014 - 2024 (USD Million)

4.1.4. Rest of the World

4.1.4.1. Market estimates and forecast, 2014 - 2024 (USD Million)

4.1.4.2. Market estimates and forecast, by indication, 2014 - 2024 (USD Million)

Chapter 5. Competitive Landscape

5.1. Competitive landscape analysis, 2016

5.2. Strategic framework

5.3. Potential customer base concentration

5.4. Company market positioning

5.5. Company profiles

5.5.1. Dr. Reddy’s Laboratories Ltd.

5.5.1.1. Company Overview

5.5.1.2. Product Benchmarking

5.5.1.3. Financial Performance

5.5.1.4. Recent Initiatives

5.5.2. Mylan

5.5.2.1. Company Overview

5.5.2.2. Product Benchmarking

5.5.2.3. Financial Performance

5.5.2.4. Recent Initiatives

5.5.3. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

5.5.3.1. Company Overview

5.5.3.2. Product Benchmarking

5.5.3.3. Financial Performance

5.5.3.4. Recent Initiatives

5.5.4. Pfizer Inc.

5.5.4.1. Company Overview

5.5.4.2. Product Benchmarking

5.5.4.3. Financial Performance

5.5.4.4. Recent Initiatives

5.5.5. Sandoz International GmbH

5.5.5.1. Company Overview

5.5.5.2. Product Benchmarking

Follow Us:

your catalyst to a lucrative business 4

Your Catalyst To a Lucrative Business

5.5.5.3. Financial Performance

5.5.5.4. Recent Initiatives

5.5.6. Teva Pharmaceuticals Industries Ltd.

5.5.6.1. Company Overview

5.5.6.2. Product Benchmarking

5.5.6.3. Financial Performance

5.5.6.4. Recent Initiatives

5.5.7. Amgen Inc.

5.5.7.1. Company Overview

5.5.7.2. Product Benchmarking

5.5.7.3. Financial Performance

5.5.7.4. Recent Initiatives

5.5.8. STADA Arzneimittel AG

5.5.8.1. Company Overview

5.5.8.2. Product Benchmarking

5.5.8.3. Financial Performance

5.5.8.4. Recent Initiatives

5.5.9. Biocon

5.5.9.1. Company Overview

5.5.9.2. Product Benchmarking

5.5.9.3. Financial Performance

5.5.9.4. Recent Initiatives

5.5.10. F. Hoffmann-La Roche Ltd.

5.5.10.1. Company Overview

5.5.10.2. Product Benchmarking

5.5.10.3. Financial Performance

5.5.10.4. Recent Initiatives

5.5.11. List of other vendors

Chapter 6. Methodology and Scope

6.1. Research methodology

6.2. Research Scope & Assumptions

6.3. List of data sources

Follow Us:

your catalyst to a lucrative business 5

Your Catalyst To a Lucrative Business

About Us:

Hexa Research is a market research and consulting organization, offering industry reports, custom research

and consulting services to a host of key industries across the globe. We offer comprehensive business

intelligence in the form of industry reports which help our clients obtain clarity about their business

environment and enable them to undertake strategic growth initiatives.

Contact Us:

Ryan Shaw

Hexa Research

Felton Office Plaza

6265 Highway 9

Felton, California 95018

United States

Phone: +1-800-489-3075

Email: sales@hexaresearch.com

Website - https://www.hexaresearch.com/

Follow Us: